Development and validation of a pharmacogenomics reporting workflow based on the illumina global screening array chip

Area of Science:

• Genomics and Bioinformatics
• Clinical Genetics
• Pharmacogenomics

Background:

• Microarrays are established tools for large-scale human genome analysis, cost-effectively identifying genetic variants.
• Imputation enhances microarray utility by covering ungenotyped common variants, crucial for genetic association studies.
• Applications extend to pharmacogenomics, nutrigenetics, and disease risk prediction, necessitating robust validation for clinical reporting.

Purpose of the Study:

• To perform pre-clinical validation of a genetic testing workflow.
• To evaluate the accuracy and precision of genotype and star-allele calls for pharmacogenomic genes.
• To assess the workflow's reliability and reproducibility for clinical readiness.

Main Methods:

• Utilized the Illumina Global Screening Array for genetic testing of 25 pharmacogenomic-related genes.
• Conducted accuracy and precision assessments using 73 cell lines, including reference materials from Genome-In-A-Bottle (GIAB) and Genetic Testing Reference Material Coordination Program (GeT-RM).
• Compared genotype and star-allele calls against established truth sets and 1000 Genomes project (1KGP) data.

Main Results:

• Achieved a mean analytical sensitivity of 99.39% and specificity of 99.98% for genotype calls.
• Reported an average diplotype concordance rate of 96.47% across 14 pharmacogenomic genes with star-allele calls.
• Demonstrated high inter-run concordance: 99.48% for diplotypes and 100% for phenotypes, indicating excellent reproducibility.

Conclusions:

• The comprehensive validation confirms the robustness and reliability of the genetic testing workflow.
• The demonstrated performance supports the workflow's suitability for clinical application development.
• This validated workflow is poised to advance pharmacogenomic testing and personalized medicine.